Literature DB >> 31773249

Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.

Santiago Montes-Moreno1, Rebecca L King2, Ilske Oschlies3, Maurilio Ponzoni4, John R Goodlad5, Snjezana Dotlic6, Alexandra Traverse-Glehen7, German Ott8, Judith A Ferry9, Maria Calaminici10.   

Abstract

This paper summarizes two sessions of the workshop during the XIX meeting of the European Association for Haematopathology (EAHP) held in Edinburgh in September 2018 dedicated to lymphomas of the gastrointestinal tract. The first session focused on the clinical and pathological features of primary gastrointestinal T cell and NK-cell lymphoproliferative disorders. The distinction between precursor lesions (RCD type 2) and enteropathy-associated T cell lymphoma were stressed, including the discussion of new diagnostic markers for the identification of aberrant phenotypes. Indolent T cell lymphoproliferative disorders of the gastrointestinal tract cases showed phenotypic heterogeneity with novel molecular alterations in few cases, such as STAT3-JAK2 fusion. In addition, novel clonal markers of disease, such as AXL and JAK3 somatic variants support the neoplastic nature of NK-cell enteropathy. The session on gastrointestinal tract B cell lymphoproliferations was dedicated to B cell lymphoproliferative disorders that arise primarily in the gastrointestinal tract (i.e., duodenal-type follicular lymphoma) or preferentially involve the digestive tract, such as large B cell lymphoma with IRF4 translocation and mantle cell lymphoma (MCL), including diverse molecular subtypes (i.e., CCND3-positive MCL mimicking MALT lymphoma). Challenging cases of high-grade B cell lymphomas with complex genetic profiles demonstrated the usefulness of novel molecular diagnostic methods such as targeted NGS to identify high-risk genetic features with potential clinical impact.

Entities:  

Keywords:  Indolent lymphoproliferative disorders; Primary gastrointestinal; T cell lymphomas

Mesh:

Year:  2019        PMID: 31773249     DOI: 10.1007/s00428-019-02704-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  6 in total

1.  CD8-positive indolent T-Cell lymphoproliferative disorder of the gastrointestinal tract: A case report and review of literature.

Authors:  Chun-Yan Weng; Cheng Ye; Yi-Hong Fan; Bin Lv; Chun-Li Zhang; Meng Li
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

Review 2.  Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders.

Authors:  Susan Swee-Shan Hue; Siok-Bian Ng; Shi Wang; Soo-Yong Tan
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

Review 3.  Mucosal Epithelial Jak Kinases in Health and Diseases.

Authors:  Narendra Kumar; Longxiang Kuang; Ryan Villa; Priyam Kumar; Jayshree Mishra
Journal:  Mediators Inflamm       Date:  2021-03-16       Impact factor: 4.711

4.  Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract: a tricky diagnosis of a gastric case.

Authors:  Magda Zanelli; Maurizio Zizzo; Francesca Sanguedolce; Giovanni Martino; Alessandra Soriano; Stefano Ricci; Carolina Castro Ruiz; Valerio Annessi; Stefano Ascani
Journal:  BMC Gastroenterol       Date:  2020-10-14       Impact factor: 3.067

Review 5.  Gastrointestinal lymphoproliferative lesions: a practical diagnostic approach.

Authors:  Marco Pizzi; Elena Sabattini; Paola Parente; Alberto Bellan; Claudio Doglioni; Stefano Lazzi
Journal:  Pathologica       Date:  2020-09

Review 6.  The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells.

Authors:  Giuseppe Ingravallo; Roberto Tamma; Giuseppina Opinto; Tiziana Annese; Francesco Gaudio; Giorgina Specchia; Tommasina Perrone; Pellegrino Musto; Gerardo Cazzato; Emilio Bellitti; Saverio Capodiferro; Eugenio Maiorano; Domenico Ribatti
Journal:  Diagnostics (Basel)       Date:  2022-02-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.